Universe Pharmaceuticals Inc's ROA from the fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Universe Pharmaceuticals Inc's ROA in the fourth quarter of 2025?
Universe Pharmaceuticals Inc had a negative return on assets (ROA) of -5.26%, due to the net loss of $-3 billion, during the twelve months ending in the fourth quarter of 2025.

However, within the Healthcare sector 261 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 3050.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Sep 30 2023) IV. Quarter
Y / Y Total Assets Change	21.1 %	206102.56 %	166463.85 %	8473.76 %	137443.3 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-3,672	-6	-6	-6	-6
Return On Assets (TTM)	-5.26 %	-0.01 %	-0.01 %	-0.02 %	-0.04 %
UPC's Total Ranking	# 3050	#	#	#	# 3507
Total Assets (TTM) in million	70,006	69,303	70,006	70,006	57,809
Seq. Total Assets Change	1.01 %	-1 %	0 %	21.1 %	171901.36 %
Seq. Net Income Change	-	-	-	-	-

UPC's 5 Years Annual ROA >> Back to UPC Management Effectiveness >> Compare UPC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 89
Sector	# 262
Overall	# 3018

Return On Assets Statistics
High	Average	Low
-5.3 %	-11.9 %	-14.77 %
(Sep 30 2025)		(Sep 30 2023)

Financial Statements
Universe Pharmaceuticals Inc's Assets	$ 70,006 million	UPC's Balance sheet
Universe Pharmaceuticals Inc's Income	$ -3,672 million	Quarterly UPC's Income Statement
UPC's Income by Division		See UPC's Income by Division

Annual Return On Assets	(Sep 30 2025) FY 2025	(Sep 30 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021
Y / Y Total Assets Change	24.65 %	2514.09 %	6066.71 %	-33.73 %	-
Total Assets in million	75,971	60,945	2,331	38	57
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-3,672	-8,727	-6	-9	11
Annual Return On Assets	-4.83 %	-14.32 %	-0.26 %	-23.11 %	19.84 %

UPC's 5 Years Annual ROA >> Back to UPC Management Effectiveness >> Compare UPC ROA to its Competitors

More Return On Assets Ratios
UPC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
UPC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for UPC's Competitors
Subscribers only: Roa for Universe Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for UPC's Customers

You may also want to know
UPC's Roi	UPC's Inventory Turnover Ratio	UPC's Growth Rates	UPC's Dividend Comparisons
	UPC's Profitability Ratios	UPC's Asset Turnover Ratio	UPC's Dividend Growth
UPC's Roe	UPC's Valuation Ratios	UPC's Financial Strength Ratios	UPC's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-07-07T13:48:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.